Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AVITA Medical (RCEL) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for AVITA Medical (RCEL) over the last 7 years, with Q4 2025 value amounting to $14.0 million.

  • AVITA Medical's Cash & Equivalents fell 3647.71% to $14.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $14.0 million, marking a year-over-year decrease of 3647.71%. This contributed to the annual value of $14.0 million for FY2025, which is 3647.71% down from last year.
  • According to the latest figures from Q4 2025, AVITA Medical's Cash & Equivalents is $14.0 million, which was down 3647.71% from $15.4 million recorded in Q3 2025.
  • Over the past 5 years, AVITA Medical's Cash & Equivalents peaked at $115.1 million during Q1 2021, and registered a low of $12.2 million during Q2 2025.
  • Its 5-year average for Cash & Equivalents is $35.7 million, with a median of $22.9 million in 2022.
  • In the last 5 years, AVITA Medical's Cash & Equivalents plummeted by 7937.43% in 2022 and then surged by 11353.77% in 2023.
  • AVITA Medical's Cash & Equivalents (Quarter) stood at $55.7 million in 2021, then plummeted by 67.4% to $18.2 million in 2022, then grew by 21.77% to $22.1 million in 2023, then changed by 0.0% to $22.1 million in 2024, then tumbled by 36.48% to $14.0 million in 2025.
  • Its Cash & Equivalents was $14.0 million in Q4 2025, compared to $15.4 million in Q3 2025 and $12.2 million in Q2 2025.